[{"orgOrder":0,"company":"Mitokinin","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"MTK-458","moa":"PINK1","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mitokinin","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mitokinin \/ AbbVie Inc","highestDevelopmentStatusID":"5","companyTruncated":"Mitokinin \/ AbbVie Inc"},{"orgOrder":0,"company":"Mitokinin","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"MTK-458","moa":"PINK1","graph1":"Neurology","graph2":"IND Enabling","graph3":"Mitokinin","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mitokinin \/ AbbVie Inc","highestDevelopmentStatusID":"5","companyTruncated":"Mitokinin \/ AbbVie Inc"}]

Find Clinical Drug Pipeline Developments & Deals by Mitokinin

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AMWC Asia-TDAC
                          Not Confirmed
                          AMWC Asia-TDAC
                          Not Confirmed

                          Details : Through the acquisition, AbbVie strengthens its neuroscience pipeline, including Mitokinin's lead compound, MTK-458, a selective PINK1 activator, designed to address mitochondrial dysfunction and potentially first-in-class disease-modifying treatment for...

                          Product Name : MTK-458

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          May 10, 2023

                          Lead Product(s) : MTK-458

                          Therapeutic Area : Neurology

                          Highest Development Status : IND Enabling

                          Sponsor : AbbVie Inc

                          Deal Size : $654.0 million

                          Deal Type : Acquisition

                          blank

                          02

                          AMWC Asia-TDAC
                          Not Confirmed
                          AMWC Asia-TDAC
                          Not Confirmed

                          Details : Under the terms of the agreement, Mitokinin will receive an upfront payment and will continue developing its PINK1 activator program of MTK-458 through completion of IND enabling studies for Mitokinin's lead compound.

                          Product Name : MTK-458

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          February 03, 2021

                          Lead Product(s) : MTK-458

                          Therapeutic Area : Neurology

                          Highest Development Status : IND Enabling

                          Sponsor : AbbVie Inc

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank